Aditxt, Inc.
Life sciences company developing immune monitoring and immune-reprogramming technologies. Operates a CLIA/CAP high-complexity laboratory for high-throughput immune biomarker profiling and is developing nucleic acid–based therapeutics designed to induce immune tolerance for transplantation, autoimmune diseases, and allergies. The company pursues commercialization, partnerships, and facility scale-up to support diagnostic services and clinical development.
Industries
Nr. of Employees
medium (51-250)
Products
Personalized immune profile reports
Multi-assay reports combining serology and neutralizing antibody measurements and other immune biomarkers to provide a comprehensive assessment of an individual's immune status.
Nucleic acid–based immune-reprogramming therapeutic candidates
Preclinical therapeutic candidates using apoptotic DNA approaches designed to induce antigen-specific immune tolerance for organ transplantation, autoimmune diseases, and allergies.
Personalized immune profile reports
Multi-assay reports combining serology and neutralizing antibody measurements and other immune biomarkers to provide a comprehensive assessment of an individual's immune status.
Nucleic acid–based immune-reprogramming therapeutic candidates
Preclinical therapeutic candidates using apoptotic DNA approaches designed to induce antigen-specific immune tolerance for organ transplantation, autoimmune diseases, and allergies.
Services
Provision of CLIA/CAP-compliant immune monitoring tests and personalized immune profile reports from high-complexity laboratory assays; services intended for clinicians, researchers, channel partners, and individuals.
Provision of CLIA/CAP-compliant immune monitoring tests and personalized immune profile reports from high-complexity laboratory assays; services intended for clinicians, researchers, channel partners, and individuals.
Expertise Areas
- Immune monitoring and diagnostics
- Immune tolerance therapeutics
- Nucleic acid-based therapeutic development
- Multiplex serology and neutralizing antibody assays
Key Technologies
- Nucleic acid-based immune tolerance therapeutics
- Plasmid DNA engineering and CpG methylation
- Apoptosis-inducing gene co-delivery
- Multiplex serological assays (IgM/IgA/IgG against multiple antigens)
News & Updates
Announcement of plans to establish a CLIA/CAP immune monitoring center in Richmond with targeted capital investment and projected job creation to scale immune monitoring capacity.
Company announcement describing facility plans, projected capacity (up to 10 million reports annually), and job creation over three years.
Publication describing expansion of the immune monitoring test to include high-sensitivity neutralizing antibody quantification and multi-antigen, multi-isotype assays to better characterize immune responses.
Designation of Richmond location as a CLIA-certified, CAP-accredited, high-complexity immune monitoring center.
Reported portfolio including multiple U.S. and non-U.S. issued patents and pending applications (company cited counts as of April 2020).
Announcement of plans to establish a CLIA/CAP immune monitoring center in Richmond with targeted capital investment and projected job creation to scale immune monitoring capacity.
Company announcement describing facility plans, projected capacity (up to 10 million reports annually), and job creation over three years.
Publication describing expansion of the immune monitoring test to include high-sensitivity neutralizing antibody quantification and multi-antigen, multi-isotype assays to better characterize immune responses.
Designation of Richmond location as a CLIA-certified, CAP-accredited, high-complexity immune monitoring center.
Reported portfolio including multiple U.S. and non-U.S. issued patents and pending applications (company cited counts as of April 2020).